The intelligence layer that scores your trial's operational risk, with calibrated specialists behind every call.
oPoS structures risk across the 14 Killer Factors. VeriAbyss™ checks the assessment for internal consistency. Astrid AI tracks regulatory drift in real time. Then a retained specialist calibrates the output against what an inspector would actually find — because a score is only worth what it's measured against.
Or request an Introductory Founder Consult →You do not need mature sponsor infrastructure to start asking mature sponsor questions.
One intelligence platform across protocol risk, operations, and regulatory drift.
oPoS scores the 14 Killer Factors. VeriAbyss™ checks the assessment for internal consistency. Astrid AI tracks regulatory change in real time. The dashboard ties every active review, risk level, and next action together — so the judgment is grounded in structured signal, not opinion.
Welcome back, Alex
3 active reviews · 1 needs attention
Recent Activity
A single view of every active review, its risk level, and what needs attention next.
Software can map a process. It cannot navigate the culture of a clinical team.
Automated platforms give you a score. They cannot tell you whether that score matches what an inspector would actually find — because they have never sat across from one. That gap is where trials fail.
The benchmark, not the checklist
A score is only worth what it is measured against. We calibrate against real inspection outcomes — the pattern of what inspectors actually find, not what a tool calculates from your own data.
The human governance layer
The SOPs, decision-owner mapping, and escalation pathways that turn a signal into a defensible decision. Software generates the alert; we build the team that can act on it and prove it later.
A living framework
When a regulator updates a requirement, our framework adapts and the audit trail shows it — logged, dated, immutable. A static product feature cannot do that.
We are the readiness layer that makes risk-based quality management work.
Most clinical teams we talk to already have — or are evaluating — a RBQM platform to detect risk in their trial. The part nobody sells you is the operational foundation that makes those signals actionable. That is what we build.
Your RBQM platform detects risk
CluePoints, Medidata RBM, Veeva CDB, Cyntegrity — they surface signals: site deviations, data quality flags, enrollment risk. That is the detection layer.
Your team has to act on it
A signal only matters if a named owner can act on it through a documented path. Without SOPs, governance, and escalation rules, detection becomes noise — alerts pile up with no decision behind them.
BleuConsult builds the layer in between
We are the readiness layer: the SOPs, decision-owner mapping, governance, and escalation pathways that turn a platform signal into a defensible, inspection-ready decision. Then we stay on as your calibration partner for the judgment calls a tool cannot make.
In one sentence
A RBQM platform tells you something is wrong. BleuConsult makes sure your team can decide what to do about it — and prove it later.
No enterprise software required. No full-time hire needed. We work with early-stage and emerging biotech teams before the platform, alongside it, or when the alerts have already started piling up.
What we deliver
- Calibrated scoring against real inspection outcomes — not a self-assessment
- Blind-spot detection: the dimensions your team under-scores
- Human governance layer: SOPs, decision-owner mapping & escalation pathways
- Living ICH E6(R3) framework that evolves with every regulatory change
- A retained specialist who knows what the output means — and stands behind it
- Risk inversion: the math of inspection failure vs. proactive calibration
What "prove it later" actually means
Compliance says you followed a rule. Defensibility means you can show the reasoning, the owner, and the evidence — under inspection, years later. BleuConsult builds the second, not just the first.
A named owner for every signal
Each risk signal routes to a specific, accountable person — not a dashboard someone glances at.
A documented escalation path
The owner follows an SOP-defined path to act — not an improvised judgment call made under pressure.
An audit-trail entry per decision
Who decided, what was decided, when, and on what evidence — captured as it happens, not reconstructed later.
An inspection-ready evidence thread
Detection, decision, and action are linked and retrievable — defensible under audit, years later.
Aligned to ICH E6(R3) and 21 CFR Part 11 — but the point is operational defensibility, not a checkbox.
Don’t take our word for it.
Take our audit trail.
Most companies claim compliance. We can show ours. Every time the ICH E6(R3) framework changes, we log an immutable version record — what changed, which dimensions it touched, and when. That’s what defensible looks like, and it’s the same system we build for you.
Live data — updated on every regulatory change.
A focused first conversation for early teams that need a sharper view of the operational risks forming underneath the plan.
Early biotech companies are often asked to make sponsor-level decisions before they have sponsor-level infrastructure. The science may be strong. The platform may be promising. The team may have advisors, vendors, investors, and a development plan. But the operational questions arrive early.
BleuConsult's Introductory Founder Consult is designed for that stage.
This consult helps founders identify where operational risk is forming underneath the plan — before it becomes expensive.
Small biotech companies don't fail because of science.
They fail because operations break under growth pressure.
You might already feel it:
BleuConsult helps you see those risks before they become expensive – no enterprise software required, no full-time hire needed.
Don't just take our word for it.
Hear from founders and clinical leaders who have pressure-tested their operations with BleuConsult.
Be among our first featured clients
BleuConsult is a young calibration practice. As founders work with us and share their results, their stories will appear here. If you've partnered with us and want to share your experience, we'd welcome your testimonial.
ICH E6(R3) Aligned
Calibration methodology strictly aligned with the latest GCP guidelines for sponsor oversight.
Enterprise-Grade Privacy
Your protocols and IP are secured within isolated, encrypted environments.
Audit-Ready Quality
Documentation and recommendations designed to withstand investor and regulatory diligence.
Common Questions
Request an Introductory Founder Consult
If your team is early, moving fast, and trying to understand what operational risks may be forming underneath the plan, request an Introductory Founder Consult with BleuConsult.
Compliance & Transparency
oPoS is an advisory decision-support tool designed to assist clinical trial planning. It does not replace professional regulatory judgment. The methodology is designed to support ICH E6(R3)-aligned assessment, sponsor oversight documentation, and decision evidence. The platform may process business contact information, uploaded protocol materials, and other user-provided content. Do not upload PHI unless appropriate agreements and safeguards are in place. VeriAbyss™ provides AI-assisted consistency review; outputs remain advisory until qualified human review.
© 2026 BleuConsult. All methodologies, frameworks, assessment logic, and library materials are the proprietary intellectual property of BleuConsult. All rights reserved.
All assessments are for informational purposes only.
